Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Increasing the efficacy of PD-1 inhibitors in HL using combination strategies

David Bond • 16 Jun 2023
ICML 2023
Hodgkin Lymphoma Lymphoma Antibodies Checkpoint inhibitors Nivolumab Pembrolizumab

David Bond, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, summarizes various combination approaches being explored with PD-1 inhibitors for the treatment of Hodgkin lymphoma (HL), including combinations with LAG-3 inhibitors, chemotherapy, and antibody-drug conjugates (ADCs). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from David Bond

1:15
SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma
David Bond • 16 Jun 2023
2:29
Evaluating the combination of nivolumab and lenalidomide in relapsed HL and LBCL
David Bond • 16 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals